Dry eye gains importance in glaucoma care
New treatments and greater awareness are making dry eye an even more important part of glaucoma care, according to Richard Lewis, MD, of Sacramento Eye Consultants.

“The treatment has really improved,” said Dr. Lewis at the 21st annual Glaucoma Symposium during the Glaucoma 360 meeting. He cited lifitegrast (Xiidra, Shire), which gained FDA approval in July 2016, and an experimental new nasal nerve stimulator (TrueTear, Allergan), whose new drug application is now under FDA consideration.

As a result, glaucoma specialists must pay more attention to the condition.“Not many people in glaucoma want to talk about dry eye,” he said. “We all have patients, and we wish they would go elsewhere. But they’re not going elsewhere.”Depending on the definition of the condition, estimates of the prevalence range from 7.8% for 48.0%, but Dr. Lewis considers the Beaver Dam study figure of 14.4% closest to the reality.